Her practice is focused on cross-border M&A transactions, foreign direct investments in China and other general corporate and commercial matters with a focus on the life sciences sector.
Her practice also includes China-related regulatory matters in the life sciences industry. She has extensive experience advising pharmaceutical, medical device, healthcare, food and cosmetics companies on issues including clinical trials, marketing authorisations, GxP compliance, ADE/AE reporting and marketing / promotional activities.
Novartis on the RMB790m (US$110m) sale of all of the equity interests in Suzhou Novartis Pharma Technology Co., Ltd. (except for its technology and drug development assets) to Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (including the carve-out and transitional service arrangements)
Fresenius Kabi on its joint venture with Vifor Pharma in China and distribution arrangement for IV iron products
Beiersdorf AG on its acquisition of Coppertone from Bayer with respect to the China regulatory matters
Roche on its (i) commercial and related pharmaceutical regulatory advice in relation to an arrangement for product development, clinical trials and eventual commercialisation of a pipeline Roche product in China; and (ii) regulatory and contractual advice in relation to setting up toll-manufacturing of a new product and transfer of pharmaceutical product registrations in China
Guangdong Wencan Die Casting on the EUR251m acquisition of the controlling stake in Le Bélier, a French listed company
SDIC Mining on its US$502m acquisition of approximately 28 per cent of shares in Jordan-based Arab Potash Company listed on the Amman Stock Exchange from Nutrien
Starbucks on the US$1.3bn buy-out of its East China joint venture from its long-term joint venture partners Uni-President Enterprises Corporation and President Chain Store Corporation, the deal marks the biggest acquisition in the history of Starbucks